BTIG Downgrades Imperva (IMPV) to Neutral

October 3, 2016 6:55 AM EDT
Get Alerts IMPV Hot Sheet
Price: $40.35 --0%

Rating Summary:
    19 Buy, 10 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 29 | Down: 30 | New: 23
Trade IMPV Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

BTIG downgraded Imperva (NYSE: IMPV) from Buy to Neutral and removed its price target. Analyst Joel P. Fishbein, Jr. sees balanced risk-reward.

"The stock is up ~23% since a report surfaced last week revealing potential acquirers, with bids due this week. We still think a deal could happen, but believe any premium is limited given where the stock is currently trading. On the flip side, our checks on the business itself are mixed, and turnover continues to be an issue in light of the sale process. We don’t think there’s risk to quarterly expectations (since the company drastically reduced FY revenue guidance by $50m/26%), but there is added risk in the stock if the process drags on (or if a deal fails to materialize altogether). Instead, we think it best for investors to move to the sidelines," said Fishbein.

For an analyst ratings summary and ratings history on Imperva click here. For more ratings news on Imperva click here.

Shares of Imperva closed at $53.71 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Downgrades

Related Entities


Add Your Comment